REFERENCES
1. Sasaki K, Bhatia V, Asano Y, et al. Collagen-binding IL-12-armoured STEAP1 CAR-T cells reduce toxicity and treat prostate cancer in mouse models. Nat Biomed Eng. 2025;10:630-46.
2. Chen S, Lu K, Hou Y, et al. YY1 complex in M2 macrophage promotes prostate cancer progression by upregulating IL-6. J Immunother Cancer. 2023;11:e006020.
3. Nag N, Dutta S. Deubiquitination in prostate cancer progression: role of USP22. J Cancer Metastasis Treat. 2020;6:16.
4. Li H, Melnyk JE, Fu BXH, et al. Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer. Nat Genet. 2025;57:3027-38.
5. De Laere B, Crippa A, Discacciati A, et al. Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial. Nat Med. 2024;30:3291-302.
6. Li W, Chen S, Lu J, et al. YY1 enhances HIF-1α stability in tumor-associated macrophages to suppress anti-tumor immunity of prostate cancer in mice. Nat Commun. 2025;16:6261.
7. Tilki D, Van Den Bergh RC, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II—2024 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2024;86:164-82.
8. Jiang W, Gan D, Johnson MH, Latich I, Lee FY. Advancements in minimally invasive interventional oncology procedures for painful sacral metastases under imaging guidance. EngMedicine. 2025;2:100051.
9. Wu S, Powers S, Zhu W, Hannun YA. Substantial contribution of extrinsic risk factors to cancer development. Nature. 2015;529:43-7.
10. Dong B, Xu J, Huang Y, et al. Integrative proteogenomic profiling of high-risk prostate cancer samples from Chinese patients indicates metabolic vulnerabilities and diagnostic biomarkers. Nat Cancer. 2024;5:1427-47.
11. Bergom HE, Boytim E, Mcsweeney S, et al. Androgen production, uptake, and conversion (APUC) genes define prostate cancer patients with distinct clinical outcomes. JCI Insight. 2024;9:e183158.
12. Soni N, Das T, Baidya M. Structural insights into an intracellular biased agonist for GPCRs. Nat Struct Mol Biol. 2023;30:1612-4.
13. Congreve M, De Graaf C, Swain NA, Tate CG. Impact of GPCR structures on drug discovery. Cell. 2020;181:81-91.
14. Hou Y, Lu H, Chen S, et al. Investigation of GPR137C as a promising novel marker for the progression of prostate cancer through G4 screen and bioinformatics analyses. Front Immunol. 2025;16:1576835.
15. Herrera LPT, Andreassen SN, Caroli J, et al. GPCRdb in 2025: adding odorant receptors, data mapper, structure similarity search and models of physiological ligand complexes. Nucleic Acids Res. 2025;53:D425-35.
16. Jiang G, Wang Z, Cheng Z, et al. The integrated molecular and histological analysis defines subtypes of esophageal squamous cell carcinoma. Nat Commun. 2024;15:8988.
17. Nieto Gutierrez A, Mcdonald PH. GPCRs: emerging anti-cancer drug targets. Cell Signal. 2018;41:65-74.
18. Khan S, Simsek R, Fuentes JDB, Vohra I, Vohra S. Implication of toll-like receptors in growth and management of health and diseases: special focus as a promising druggable target to Prostate Cancer. Biochim Biophys Acta Rev Cancer. 2025;1880:189229.
19. Feng Q, Li S, Ma H, Yang W, Zheng P. LGR6 activates the Wnt/β-catenin signaling pathway and forms a β-catenin/TCF7L2/LGR6 feedback loop in LGR6high cervical cancer stem cells. Oncogene. 2021;40:6103-14.
20. Wang J, Koch DT, Hofmann FO, et al. WNT enhancing signals in pancreatic cancer are transmitted by LGR6. Aging. 2023;15:205101.
21. Crowley L, Cambuli F, Aparicio L, et al. A single-cell atlas of the mouse and human prostate reveals heterogeneity and conservation of epithelial progenitors. eLife. 2020;9:e59465.
22. Chen S, Zhu G, Yang Y, et al. Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. Nat Cell Biol. 2021;23:87-98.
23. Ping Y, Xiao P, Yang F, et al. Structural basis for the tethered peptide activation of adhesion GPCRs. Nature. 2022;604:763-70.
24. Munk C, Isberg V, Mordalski S, et al. GPCRdb: the G protein‐coupled receptor database - an introduction. Br J Pharmacol. 2016;173:2195-207.
25. Turku A, Schihada H, Kozielewicz P, Bowin C, Schulte G. Residue 6.43 defines receptor function in class F GPCRs. Nat Commun. 2021;12:3919.
26. Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.
27. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.
28. Robinson MD, Mccarthy DJ, Smyth GK. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139-40.
29. Wu T, Hu E, Xu S, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation. 2021;2:100141.
30. Abramson J, Adler J, Dunger J, et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024;630:493-500.
31. Schmitz S, Ertelt M, Merkl R, Meiler J. Rosetta design with co-evolutionary information retains protein function. PLoS Comput Biol. 2021;17:e1008568.
32. Del Conte A, Monzon AM, Clementel D, et al. RING-PyMOL: residue interaction networks of structural ensembles and molecular dynamics. Bioinformatics. 2023;39:btad260.
33. Yu S, Mulero MC, Chen W, et al. Therapeutic targeting of tumor cells rich in LGR stem cell receptors. Bioconjugate Chem. 2021;32:376-84.
34. Tocci JM, Felcher CM, García Solá ME, et al. R-spondin3 is associated with basal-progenitor behavior in normal and tumor mammary cells. Cancer Res. 2018;78:4497-511.
35. Scharr M, Scherer S, Fuchs J, Hirt B, Neckel PH. R-spondin1 regulates fate of enteric neural progenitors via differential LGR4/5/6 expression in mice and humans. Cell Mol Gastroenterol Hepatol. 2026;20:101642.
